Page 103 - GTM-2-1
P. 103

Global Translational Medicine                                       GalNAc AGT ASO reduce atherosclerosis




                         A












                         B                                  C














                                                                       E
                         D












            Figure 1. Antisense oligonucleotides (ASO) targeting hepatic angiotensinogen (AGT) reduced plasma AGT concentrations, systolic blood pressure, and
            atherosclerotic lesion area in the thoracic aorta. (A) Experimental protocol. (B) Plasma AGT concentrations on weeks -2, 0, 4, and 11 during ASO
            administration. A piecewise mixed-effect model was fitted to examine slopes for distinct time points (-2 to 0 and 0 to 11 weeks). Doses 1, 2.5, and 5 mg/
            kg led to profound reductions in plasma AGT concentrations compared to week -2; P < 0.001. (C) Mouse systolic blood pressure (BP) on weeks -2, 3, 7,
            and 11. A mixed-effect model was used to compare slopes among the four groups. Doses 1, 2.5, and 5 mg/kg led to significant reductions in systolic BP
            compared to week -2; P < 0.001. (D) En face aorta images, scale bar = 1 mm. (E) Atherosclerotic lesion area of the thoracic aorta normalized by total intimal
            surface area; N = 6–10 per group.
            GalNAc  AGT  ASO:  N-acetylgalactosamine-conjugated  antisense  oligonucleotides  targeting  angiotensinogen;  PBS:  Phosphate-buffered  saline;
            SQ: Subcutaneous.


            2.3. Plasma profiles                               #: IB59131, IBL-America) after being incubated with

            Mouse blood was collected in the presence of       exogenous recombinant mouse AGT for 1 h.
            ethylenediaminetetraacetic  acid  (EDTA;   final     Plasma alanine aminotransferase (ALT) and aspartate
            concentration: 1.8  mg/mL) through submandibular   aminotransferase (AST) were measured on the Olympus
            bleeding during the study. At termination, blood was   AU400 clinical analyzer (Olympus, Center Valley, PA)
            collected through cardiac bleeding through the right   using L-Type  ALT.J2 and L-Type  AST.J2 reagents and
            ventricle. Plasma AGT concentrations were measured   calibrators (Fujifilm Healthcare) in Ionis in a blinded
            using a mouse AGT enzyme-linked immunosorbent assay   manner.
            (ELISA) kit (Cat # 245718, Abcam), which detects both
            intact AGT and des(AngI)AGT, thereby measuring total   2.4. Quantification of atherosclerosis
            AGT. Plasma renin concentrations in mice were measured   After euthanasia, mouse aortas were dissected and fixed in
            by an enzyme-kinetic assay using an AngI ELISA kit (Cat   10% neutrally buffered formalin overnight. Subsequently,


            Volume 2 Issue 1 (2023)                         3                         https://doi.org/10.36922/gtm.288
   98   99   100   101   102   103   104   105   106   107   108